Greenlane announces non-binding letter of intent to be the exclusive distributor in the u.s. of safety strips, inc.'s fentanyl, xylazine and drink spike detection test strips

High-sensitivity test strips offer powerful detection capability for the current and growing opiate crisis combining greenlane's industry leading omnichannel distribution platform with safety strips affordable and highly accurate iso certified test strips to help prevent opioid-related deaths boca raton, fl / accesswire / august 12, 2024 / greenlane holdings, inc. ("greenlane" or the "company") (nasdaq:gnln), one of the premier global sellers of premium cannabis accessories, child-resistant packaging, and specialty vaporization products, today announced that it has entered into a non-binding letter of intent (the "loi") to be the exclusive distributor in the u.s, of safety strips, inc.'s fentanyl, xylazine and drink spike detection test strips. safety strips, inc. testing strips "we are excited and proud to provide safety strips affordable and highly accurate tests with trace level fentanyl and xylazine detection capabilities to our customers throughout the u.s.," said barbara sher, chief executive officer for greenlane.
GNLN Ratings Summary
GNLN Quant Ranking